profit from every $100 of sales.
$0$100
Sanofi
$48.46+0.06% today
-6.7% in 1 year
1-year low $39.121-year high $52.34
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $13.44 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sanofi sold, what it kept, and what it did with the cash.
Sales went from €40.6 billion in 2022 to €46.7 billion in 2025, with €7.81 billion of profit last year.
SalesProfit
Sanofi handed back more cash to shareholders than it generated last year.
Buybacks €5.0B€4.8B
Free cash flow 2025€7.2B
Bought back its own shares€5.0B
Paid as dividends€4.8B
Cash vs. debt€7.7B vs. €20.3B
Sanofi vs. similar companies
Sanofi grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sanofi | 13.4× · Cheap | ||
 Eli Lilly | 61.6× · Very expensive | ||
 Johnson & Johnson | 25.5× · Fair price | ||
 AbbVie | 123.2× · Very expensive | ||
 Roche | 25.7× · Fair price |
Compare Sanofi with AbbVie · Johnson & Johnson · Eli Lilly · Merck & · Roche · UnitedHealth
AI analysis
An AI analyst reads Sanofi's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 40,561 | 41,618 | 44,286 | 46,716 | |
| 28,679 | 28,990 | 31,081 | 33,667 | |
| 10,926 | 8,691 | 8,923 | 9,597 | |
| 13,510 | 11,323 | 10,988 | 12,479 | |
| 8,371 | 5,400 | 5,560 | 7,813 | |
| 2.69 | 2.16 | 2.30 | 3.20 | |
| 70.7% | 69.7% | 70.2% | 72.1% | |
| 26.9% | 20.9% | 20.1% | 20.5% | |
| 20.6% | 13.0% | 12.6% | 16.7% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 126,722 | 126,464 | 132,798 | 126,805 |
| Cash | 12,736 | 8,710 | 7,441 | 7,657 |
| Total debt | 21,212 | 18,422 | 17,906 | 20,329 |
| Total liabilities | 51,570 | 52,111 | 54,941 | 55,095 |
| 74,784 | 74,040 | 77,507 | 71,376 | |
| 2,504 | 2,503 | 2,503 | 2,441 | |
| 8.6% | 5.9% | 6.1% | 5.9% | |
| 11.2% | 7.3% | 7.2% | 10.9% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10,526 | 10,258 | 9,081 | 10,750 | |
| 2,103 | 2,906 | 3,195 | 3,538 | |
| 8,423 | 7,352 | 5,886 | 7,212 | |
| Dividends paid | 4,168 | 4,454 | 4,704 | 4,772 |
| 497 | 593 | 302 | 5,030 | |
| – | – | – | – |
Valuation
- 13.4×
- 11.5×
- 2.23
- 1.4×
- 2.2×
- 14.6×
- 9.4×
- 6.9%
- 7.4%
- 4.5%
Profitability
- 72.1%
- 20.5%
- 16.7%
- 18.5%
- 6.0%
- 6.8%
- 14.4%
- 8.1%
- 15.1%
- 16.7%
Growth
- +4.8%
- +6.0%
- +72.3%
- +4.6%
- −0.8%
Financial health
- 1.0×
- 0.28
- 15.6%
- 10.9×
- 1.09
- 0.22
- 0.46
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 47%of 952
Top 22%of 883
Top 18%of 576
Bottom 26%of 870
Top 13%of 985
What analysts expect
- Average price target
- $51.00
- Range
- $50.00 – $52.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 23, 2026 | 1.10 | 1.06 | +3.8% |
| Jan 29, 2026 | 0.89 | 0.84 | +6.0% |
| Oct 24, 2025 | 1.70 | 1.60 | +6.2% |
| Jul 31, 2025 | 0.90 | 0.96 | −6.2% |
| Apr 24, 2025 | 0.94 | 0.90 | +4.4% |
| Jan 30, 2025 | 0.70 | 0.71 | −1.4% |
| Oct 25, 2024 | 1.57 | 1.35 | +16.3% |
| Jul 25, 2024 | 0.93 | 0.86 | +8.1% |
4.5%of the share price, paid each year
On $1,000 invested$45a year at today's yield, before tax
+4.6%2020 to 2025
Raised2 yearsin a row, in our data
Paid per share, each year
$1.62 in 2015 → $2.20 in 2025
How safe it looks
61.1% of its profit
Room to growStretchedMore than it earns: 66.2%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
57No pass
Benjamin Graham
72Pass
Philip Fisher
64Pass
Peter Lynch
37No pass
Joel Greenblatt
31No pass
Charlie Munger
53No pass
Terry Smith
46No pass
Questions about Sanofi
Is Sanofi a good stock to buy?
A solid business, and the price looks low. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sanofi AI analysis
What does Sanofi do?
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It is in Drug Manufacturers - General, based in Paris, France, with 74,846 employees.
Does Sanofi pay a dividend?
Yes. At today's price the dividend is 4.5% a year, about 61% of its yearly profit. In 2025 it paid out $4.77 billion in dividends.
Is Sanofi stock halal?
Yes. Sanofi passes our halal screen: its business is permitted and its debt is 19% of its market value, under the 30% limit. How we check
How has Sanofi stock done over the past year?
Down 6.7% over the past twelve months, to $48.46. It traded between $39.12 and $52.34 and is 7.4% below its high.
Who are Sanofi's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Sanofi's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.